Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Why Farfetch Stock (FTCH) Is Getting Hammered

Farfetch Ltd (NASDAQ: FTCH) shares are trading lower by 47% to $1.11 Wednesday morning after the company said it will not announce third-quarter results.
byHenry Khederian
November 29, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Farfetch Ltd (NASDAQ:FTCH) shares are trading lower by 47% to $1.11 Wednesday morning after the company said it will not announce third-quarter results.

In a brief press release late Tuesday, the company said it won’t release its third quarter 2023 financial results as planned and has canceled the associated conference call.

Farfetch says the company is holding off on forecasts or guidance, advising against relying on any previously provided estimates. Instead, they plan to offer a market update in the future.

See Also: Why Verve Therapeutics Stock Is Falling

According to data from Benzinga Pro, FTCH has a 52-week high of $54.60 and a 52-week low of $27.85.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval

By Jelena Martinovic
February 13, 4:22 PM
Cannabinoid-focused pharmaceutical company Innocan Pharma Corp expects preliminary revenues of $4.89m in Q4 of fiscal 2023, representing a YoY increase of 331%. It said preliminary revenues are expected to be at least $13.6m for the whole of the fiscal year, a 433% YoY increase. Its subsidiary B.I. Sky Global drove the increase in sales. Innocan is currently pursuing FDA approval for its human pharmaceutical applications following successful pre-clinical trials, and the company expects pre-investigational new drug applications to be submitted to the FDA before the end of the month. Innocan has developed a long-lasting and therapeutic liposomal formulation for CBD called LPT Solution, which administers injectable CBD encapsulated in liposomes to achieve long-lasting therapeutic levels of CBD in the body. The company said the technology creates a more effective and prolonged therapeutic effect. Innocan plans to test the LPT platform on a new animal species in the near future.

CSE:INNO